Dr. Anne Vandewiele - Klinisch Bioloog
0534.499.791 · rovalta.com · 27/09/2026
Dr. Anne Vandewiele - Klinisch Bioloog
Financial year 2025 · Closed on 31/12/2025
Overview
Identity
Source · BCE/KBODr. Anne Vandewiele - Klinisch Bioloog is a Private limited company incorporated in 2013. Its registered office is in Tielt.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0534.499.791
- Incorporation
- 10/05/2013
- Legal form
- Private limited company
- Registered office
- Hooitstraat 4
8700 Tielt · FlandreSee on map - Contributed capital
- 12 400,00 €
- Latest accounts
- 31/12/2025
Financials
Source · NBB, 12 filingsTrend over 7 financial years
| 2025 | 2024 | 2023 | 2022 | 2021 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 176,8 k € | -3.0% | 182,3 k € | +10.5% | 165 k € | +22.4% | 134,7 k € | +14.1% | 118,1 k € |
| EBITDA | 176,2 k € | -3.1% | 181,8 k € | +10.9% | 164 k € | +22.3% | 134,1 k € | +14.1% | 117,5 k € |
| Operating result | 154,9 k € | -4.2% | 161,6 k € | +2.9% | 157,1 k € | +24.0% | 126,8 k € | +21.5% | 104,4 k € |
| Net result | 114,8 k € | -0.9% | 115,9 k € | +4.4% | 111 k € | +23.7% | 89,7 k € | +22.6% | 73,2 k € |
| Balance sheet | |||||||||
| Equity | 596,8 k € | +8.0% | 552,6 k € | +9.8% | 503,3 k € | +22.7% | 410,3 k € | +28.0% | 320,7 k € |
| Total assets | 629,5 k € | +6.4% | 591,9 k € | +11.8% | 529,4 k € | +18.2% | 447,8 k € | +21.4% | 368,7 k € |
| Cash | 402,5 k € | +91.6% | 210 k € | -49.1% | 412,9 k € | +24.3% | 332,1 k € | +34.6% | 246,7 k € |
| Debts | 32,7 k € | -14.4% | 38,3 k € | +48.4% | 25,8 k € | -31.1% | 37,4 k € | -22.1% | 48,1 k € |
Valuation
Indicative valuation
As an indication, this company is worth
Board of directors
Source · NBB, accounts to 31/12/20251 active · 3 ended
Active mandates
| Director | Function | Mandate |
|---|---|---|
Anne Vandewiele | Zaakvoerder | since 04/05/2013 |
Ended mandates
| Director | Function | Mandate |
|---|---|---|
Anne Vandewiele | Manager | since 04/05/2013 |
Maarten Ysebaert | Manager | 04/05/2013 → 01/12/2016 |
Ysebaert Maarten | Manager | 04/05/2013 → 04/05/2019 |
Financials
Full financial information
Source · NBB| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2025 | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 |
| Closing of the financial year | 31/12/2025 | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 15/09/2026 | 29/09/2025 | 28/09/2024 | 07/07/2023 | 06/07/2022 | 29/06/2021 |
| General meeting | 13/06/2026 | 14/06/2025 | 08/06/2024 | 10/06/2023 | 18/06/2022 | 29/05/2021 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 12 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2025 | 13/06/2026 | 15/09/2026 | Dutch | |
| Micro model | 31/12/2024 | 14/06/2025 | 29/09/2025 | Dutch | |
| Micro model | 31/12/2023 | 08/06/2024 | 28/09/2024 | Dutch | |
| Micro model | 31/12/2022 | 10/06/2023 | 07/07/2023 | Dutch | |
| Micro model | 31/12/2021 | 18/06/2022 | 06/07/2022 | Dutch | |
| Micro model | 31/12/2020 | 29/05/2021 | 29/06/2021 | Dutch | |
| Micro model | 31/12/2019 | 30/05/2020 | 30/06/2020 | Dutch | |
| Micro model | 31/12/2018 | 25/05/2019 | 27/08/2019 | Dutch | |
| Micro model | 31/12/2017 | 26/05/2018 | 21/09/2018 | Dutch | |
| Micro model | 31/12/2016 | 27/05/2017 | 27/09/2017 | Dutch | |
| Abridged model | 31/12/2015 | 23/09/2016 | 28/09/2016 | Dutch | |
| Abridged model | 31/12/2014 | 26/09/2015 | 30/09/2015 | Dutch |
Valuation
Indicative valuation
As an indication, this company is worth
between 1 M€ and 2,5 M€
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20251 active · 3 ended
Active mandates
| Director | Function | Mandate |
|---|---|---|
Anne Vandewiele | Zaakvoerder | since 04/05/2013 |
Ended mandates
| Director | Function | Mandate |
|---|---|---|
Anne Vandewiele | Manager | since 04/05/2013 |
Maarten Ysebaert | Manager | 04/05/2013 → 01/12/2016 |
Ysebaert Maarten | Manager | 04/05/2013 → 04/05/2019 |
Ownership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official GazetteSimilar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2025Annual accounts 2025114,8 k €↓
- 2024Annual accounts 2024115,9 k €↑
- 2023Annual accounts 2023111 k €↑
- 2022Annual accounts 202289,7 k €↑
- 2021Annual accounts 202173,2 k €↓
- 2015Annual accounts 201599,2 k €↑
- 2014Annual accounts 201476,2 k €
- 10/05/2013IncorporationPrivate limited company
Company names
Source · NBB annual accounts, CBE| Name | Period | Source |
|---|---|---|
| Dr. Anne Vandewiele - Klinisch BioloogCurrent | CBE, tracked since 27/09/2026 | CBE |
| Vandewiele Anne Dr. Kl.Bioloog | accounts 2021 → 2025 | Accounts 2025 · 2026-00516753 |
Annual accounts date a value by the financial year it appears in. The CBE dates a change to the day, but its history has only been kept since 27/09/2026.